Open House - Global Healthcare 2022: OpGen | Edison Group

Open House - Global Healthcare 2022: OpGen | Edison Group

Broadcast on: January 27, 2022
Duration: 10:16

OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.

  • Chief Executive Officer

    Oliver Schacht, Ph.D., Chief Executive Officer, OpGen

    Mr. Oliver Schacht, a corporate finance professional and expert in the molecular diagnostics industry, is the CEO of OpGen has been CEO of Curetis since April 2011 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 to end of the first quarter in 2011. He was a co-founder and CFO of Epigenomics AG (Berlin, Germany) and the CEO of Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two IPOs), as well as corporate finance, investor relations, PR, marketing and business development. Mr. Schacht also serves on the Board of ICBA as its Vice Chairman and BIO Deutschland e.V. as its president and previously as treasurer.

More from OETV

What's happening on OETV

No upcoming videos or events

We didn't find any upcoming videos or events in your selected timeframe. Change your timeframe or check back soon for more!

No upcoming videos or events

We didn't find any upcoming videos or events in your selected timeframe. Change your timeframe or check back soon for more!

X

We value your privacy

This website or its third party tools uses cookies, which are necessary for its functioning and required to achieve the purpose illustrated in our Privacy Policy. By clicking "Accept" or dismissing this notice, you agree to our website's use of cookies.